Related Experiment Video
Updated: Oct 9, 2025
08:11
Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique
Published on: November 11, 2022
3.1K
[Pharmacology of hyperkalemia]
1Centro di Ricerca Clinica e Sperimentale, Dipartimento di Scienze Mediche, IRCCS San Raffaele Pisana, Roma.
Giornale Italiano Di Cardiologia (2006)
|December 22, 2021
Summary
New potassium binders, patiromer and sodium zirconium cyclosilicate, offer effective acute and chronic hyperkalemia (HK) treatment for heart failure patients. These therapies manage serum potassium levels, enabling optimal use of crucial heart failure medications.
Area of Science:
- Cardiology
- Nephrology
- Pharmacology
Background:
- Hyperkalemia (HK) frequently affects heart failure patients due to reduced kidney function, impaired homeostasis, and cardiovascular drug effects.
- Drugs like renin-angiotensin-aldosterone system inhibitors (RAASi), angiotensin receptor-neprilysin inhibitors, and beta-blockers can induce HK by hindering potassium excretion.
Purpose of the Study:
- To review recent advancements in acute and chronic hyperkalemia (HK) management.
- To evaluate the efficacy of novel potassium-binding therapies in patients with cardio-renal conditions and heart failure.
Main Methods:
- Review of recent clinical studies and therapeutic guidelines for hyperkalemia (HK) management.
- Analysis of the clinical data for patiromer and sodium zirconium cyclosilicate in treating acute and chronic HK.
Main Results:
- Patiromer and sodium zirconium cyclosilicate demonstrate efficacy in both acute and long-term HK treatment.
- These agents significantly reduce serum potassium in patients with HK receiving RAASi.
- The new therapies facilitate the initiation and titration of RAASi in patients with suboptimal treatment.
Conclusions:
- Novel potassium binders represent a significant therapeutic advance for managing hyperkalemia (HK) in heart failure and cardio-renal patients.
- These medications improve the management of HK, allowing for better utilization of guideline-directed medical therapies, particularly RAASi.
Related Concept Videos
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
886
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
886
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
1.4K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.4K
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
979
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
979
01:26Heart Failure Drugs: Inotropic Agents
811
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
811
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.9K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.9K
01:20Antiepileptic Drugs: Potassium Channel Activators
337
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
337